Browsing Tag

CD20Targeted

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical…

Eli Pacheco Oct 6, 2022 0

Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high…

Health

Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2…

Eli Pacheco May 13, 2022 0

Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma Data to be presented…

Health

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T…

Eli Pacheco Apr 25, 2022 0

Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those…

Health

Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations

Eli Pacheco Apr 22, 2022 0

WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical…

Health

Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for…

Eli Pacheco Nov 1, 2021 0

WORCESTER, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical…